GlaxoSmithKline (GSK) and University College London's Institute of Ophthalmology have agreed a deal in which the Institute will investigate the potential of compounds provided by GSK's ophthalmic unit, Ophthiris.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.